本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Immunovant, Inc.

15.46
-0.2700-1.72%
盘后15.00-0.4600-2.98%19:35 EDT
成交量:64.69万
成交额:999.62万
市值:26.45亿
市盈率:-5.66
高:16.09
开:15.66
低:15.16
收:15.73
52周最高:34.47
52周最低:12.72
股本:1.71亿
流通股本:6,373.34万
量比:0.65
换手率:1.02%
股息:- -
股息率:- -
每股收益(TTM):-2.7303
每股收益(LYR):-2.7303
净资产收益率:-62.46%
总资产收益率:-37.97%
市净率:3.74
市盈率(LYR):-5.66

数据加载中...

公司资料

公司名字:
Immunovant, Inc.
交易所:
NASDAQ
成立时间:
2018
员工人数:
362
公司地址:
320 West 37th Street,6th Floor,New York,New York,United States
邮编:
10018
电话:
传真:
- -
简介:
Immunovant, Inc.于2018年12月6日在特拉华州注册成立,是一家临床阶段生物制药公司,专注于为自身免疫性疾病患者提供正常生活。

董事

名称
职位
Eric Venker
Chief Executive Officer and Director
Frank M. Torti
Executive Chairperson of board
Andrew Fromkin
Director
Atul Pande
Director
Douglas Hughes
Director
Jacob Bauer
Director
Robert Susman
Director

股东

名称
职位
Eric Venker
Chief Executive Officer and Director
Melanie Gloria
Chief Operating Officer
Tiago Girao
Chief Financial Officer
Christopher Van Tuyl
Chief Legal Officer and Corporate Secretary
Frank M. Torti
Executive Chairperson of board
Jay S. Stout
Chief Technology Officer
Michael Geffner
Chief Medical Officer